SCHEMBL8277249

SCHEMBL8277249

CC1(C(O)C(=O)O)CCCC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.42
NFKB1 P19838 1/20 0.42
CYP2C19 P33261 1/20 0.42
FFAR3 O14843 1/20 0.36
TP53 P04637 1/20 0.35
GRIK1 P39086 2/20 0.33
GRIK2 Q13002 1/20 0.33
MME P08473 1/20 0.32
SLC1A2 P43004 1/20 0.31
SLC1A1 P43005 1/20 0.31
DPP4 P27487 2/20 0.31
FAP Q12884 2/20 0.31
PITRM1 Q5JRX3 2/20 0.31
DPP8 Q6V1X1 2/20 0.31
DPP9 Q86TI2 2/20 0.31
DPP7 Q9UHL4 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8277960 0.98 CYP2C19 (0.41) TSHRNFKB1CYP2C19FFAR3TP53
SCHEMBL13640446 0.95 TSHR (0.47) TSHRNFKB1CYP2C19FFAR3TP53
SCHEMBL15085805 0.90
SCHEMBL8277385 0.80 TSHR (0.33) TSHRNFKB1CYP2C19FFAR3DPP4
SCHEMBL8277388 0.78 ALDH1A1 (0.34) TSHRNFKB1CYP2C19DPP4FAP
SCHEMBL13201636 0.76 TSHR (0.31) TSHRNFKB1CYP2C19
SCHEMBL8670866 0.75 CYP2C19 (0.38) TSHRNFKB1CYP2C19FFAR3MME
SCHEMBL28139936 0.75 TSHR (0.38) TSHRNFKB1CYP2C19FFAR3TP53
SCHEMBL13201634 0.75 DPP4 (0.31) TSHRNFKB1CYP2C19DPP4FAP
SCHEMBL1874859 0.73 CYP2C19 (0.36) TSHRNFKB1CYP2C19FFAR3TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388604-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2025-12-25 US disclosed
EP-4572762-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2025-06-25 EP disclosed
WO-2024038128-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS MIRONID LIMITED (GB) 2024-02-22 WO disclosed
US-7767818-B2 Hepatitis C inhibitor dipeptide analogs BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-08-03 US disclosed
US-7511157-B2 racemic mixtures, stereoisomers or optical isomers, useful as protease inhibitors; viricides BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-03-31 US disclosed
US-7511157-B2 racemic mixtures, stereoisomers or optical isomers, useful as protease inhibitors; viricides BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-03-31 US disclosed
WO-2006007700-A1 HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388604-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE7A, PDE4B TSHR 1206/4885NFKB1 3033/4885CYP2C19 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.